Patents by Inventor Gregory M. Podsakoff
Gregory M. Podsakoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7829078Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: July 15, 2008Date of Patent: November 9, 2010Assignees: Genzyme Corporation, Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20100104535Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: October 30, 2007Publication date: April 29, 2010Inventors: Gregory M. Podsakoff, Gary J. Kurtzman
-
Patent number: 7704492Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: July 15, 2008Date of Patent: April 27, 2010Assignee: Genzyme CorporationInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20090208459Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: July 15, 2008Publication date: August 20, 2009Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20080305084Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: July 15, 2008Publication date: December 11, 2008Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20080199442Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: June 22, 2007Publication date: August 21, 2008Applicants: Genzyme Corporation, Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 7238674Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: March 5, 2002Date of Patent: July 3, 2007Assignee: Genzyme CorporationInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20030219415Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: May 23, 2003Publication date: November 27, 2003Applicants: Johns Hopkins University, Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20030206889Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: June 10, 2003Publication date: November 6, 2003Inventors: Gregory M. Podsakoff, Gary J. Kurtzman
-
Patent number: 6610290Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: October 1, 2001Date of Patent: August 26, 2003Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20020155608Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: October 1, 2001Publication date: October 24, 2002Applicant: Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20020147172Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: March 5, 2002Publication date: October 10, 2002Applicant: Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 6391858Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: January 4, 2001Date of Patent: May 21, 2002Assignee: Avigen, Inc.Inventors: Gregory M. Podsakoff, Gary J. Kurtzman
-
Patent number: 6335011Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: September 28, 1999Date of Patent: January 1, 2002Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 6325998Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: December 4, 1998Date of Patent: December 4, 2001Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Gary J. Kurtzman
-
Publication number: 20010001661Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: January 4, 2001Publication date: May 24, 2001Applicant: Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 6211163Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: May 10, 1999Date of Patent: April 3, 2001Assignee: Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 5962313Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: January 16, 1997Date of Patent: October 5, 1999Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 5858351Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: January 18, 1996Date of Patent: January 12, 1999Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 5846528Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: January 16, 1997Date of Patent: December 8, 1998Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Gary J. Kurtzman